Skip to main content
Keyword
Specialties
Allergy & Immunology
Autoimmune
CardioVascular
Clinical Pathways
Dentistry
Dermatology
Emergency & Mobile Medicine
Endocrinology & Diabetes
Gastroenterology
Infectious Diseases
Neurology
Obstetrics & Gynecology
Oncology
Ophthalmology
Pediatrics
Podiatry
Population Health
Psychiatry & Behavioral Health
Pulmonology
Rheumatology & Arthritis
Surgery
Urology
Wound Care
Events
Education
About
Sign In
Search
Keyword
Specialties
Allergy & Immunology
Autoimmune
CardioVascular
Clinical Pathways
Dentistry
Dermatology
Emergency & Mobile Medicine
Endocrinology & Diabetes
Gastroenterology
Infectious Diseases
Neurology
Obstetrics & Gynecology
Oncology
Ophthalmology
Pediatrics
Podiatry
Population Health
Psychiatry & Behavioral Health
Pulmonology
Rheumatology & Arthritis
Surgery
Urology
Wound Care
Events
Education
About
Sign In
Search
Sabree Burbage
Real-World Treatment Persistence Among Advanced Therapy-Experienced Patients With Ulcerative Colitis Initiated on Ustekinumab or Adalimumab
1 Analysis Group Inc., Montréal, Quebec, Canada; 2 Janssen Scientific Affairs, LLC., Horsham, Pennsylvania, United States.
Maryia Zhdanava , MA;
Sumesh Kachroo ;
Porpong Boonmak ;
Sabree Burbage ;
Aditi Shah , MA;
Jill Korsiak ;
Patrick Lefebvre , MA;
Caroline Kerner ;
Dominic Pilon , MA;
01/11/2024
Comparison of Real-World Healthcare Resource Utilization Among Advanced Therapy-Experienced Patients With Ulcerative Colitis Initiated on Ustekinumab or Vedolizumab
1 Analysis Group Inc., Montréal, Quebec, Canada; 2 Janssen Scientific Affairs, LLC., Horsham, Pennsylvania, United States.
Aditi Shah , MA;
Jill Korsiak ;
Patrick Lefebvre , MA;
Caroline Kerner ;
Dominic Pilon , MA;
Maryia Zhdanava , MA;
Sumesh Kachroo ;
Porpong Boonmak ;
Sabree Burbage ;
01/11/2024
Treatment Persistence Among Anti-TNF-Experienced Patients With Ulcerative Colitis Switching to Ustekinumab or Cycling to Another Anti-TNF Agent
1 Analysis Group Inc., Montréal, Quebec, Canada; 2 Janssen Scientific Affairs, LLC, Horsham, Pennsylvania, United States.
Maryia Zhdanava , MA;
Sumesh Kachroo ;
Porpong Boonmak ;
Sabree Burbage ;
Aditi Shah , MA;
Patrick Lefebvre , MA;
Dominic Pilon , MA;
Bridget Godwin ;
01/11/2024
Featured CME Course
Targeted Therapies for the Management of Chronic Lymphocytic Leukemia: Evaluating the Evidence to Optimize Patient Care and Outcomes
Upcoming Events
February 2 – February 5
February 7 – February 9
February 27 – March 1
March 17 – March 19
March 22 – March 23
March 27 – March 30
March 31 – April 2
April 21 – April 24
April 30 – May 4
May 1 – May 3
See Full Calendar